CAR T-Cell Therapy Market (By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others; By Indication; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global CAR T-cell therapy market was estimated at USD 2.20 billion in 2022 and it is expected to surpass around USD 6.48 billion by 2032, poised to grow at a CAGR of 11.4% from 2023 to 2032.

Key Pointers

• By drug type, the axicabtagene ciloleucel segment was the highest revenue contributor to the CAR T-cell therapy market.
• On the basis of indication, the lymphoma segment generated maximum revenue in 2022
• On the basis of end user, the hospitals segment was the highest revenue contributor to the CAR T-cell therapy market in 2022.
• Depending on region, North America generated the highest revenue in 2022.

Increasing prevalence of cancer across the globe and rising mortality rate from cancer are expected to drive the global CAR-T cell therapy market revenue growth over the forecast period. Rapidly expanding clinical trial activities, proliferating mergers & acquisitions, and attractive initial public offerings are contributing to revenue growth of the global CAR T-cell therapy market. Consistent research on cancer and its treatment, as well as advances in medicines, further support the expansion of the market.

Chimeric antigen receptor cell therapy is a technique for altering T-cells, a kind of white blood cell in the laboratory so that they can detect malignant cells. CAR T-cell therapy is often commonly referred to as a type of cell-based gene therapy, as it modifies the genes of T cells to make them more effective at combating cancer. CAR T therapy is used to treat specific types of blood malignancies and is also being investigated for other cancer types. On 28 May 2022 for instance, Novartis announced, that the U.S. Food and Drug Administration (FDA) granted Kymriah, (tisagenlecleucel) accelerated clearance for therapy in patients with refractory follicular lymphoma after two or more lines of systemic therapy. Although the first authorized anti-CD19 CAR T treatment provided promising results, complications such as high relapse rates and resistance were encountered, necessitating the search for modified CAR T-cells that are more effective for therapeutic usage. CAR T-cell structure and manufacturing innovations have resulted in considerable gains in effectiveness and persistence, especially with the creation of fourth-gen CAR T-cells. When used in conjunction with an immune modifier, fourth-generation, and next-generation CAR T-cells will not be restricted by cytotoxic effects and will be an effective weapon for conquering the tumor microenvironment.

Chimeric antigen receptor T-cell treatments have demonstrated the potential to revolutionize cancer therapy, but their use is now restricted to patients with certain recurring and resistant liquid cancers. To understand CAR Ts full potential, investments are being done in optimizing autologous CAR Ts for liquid tumors, expanding number of healthcare settings that administer CAR T, reducing innovation processing times to enable success in solid tumors, and developing next-generation CAR T-cell therapies. CAR T-cell therapies have ample potential as immunotherapy-based cancer treatment. It involves genetically modifying T-cells from the patient or a donor to develop a chimeric antigen receptor that targets a tumor antigen precisely.

The COVID-19 pandemic had an adverse effect on the expansion of the global CAR T-cell therapy market as a result of the lockdown that disrupted the distribution of cancer medications throughout the world. The travel restrictions halted commercial operations and biopharmaceutical and life sciences industries experienced supply chain interruptions as they awaited the availability of new batches of raw materials for CAR T-cell manufacture. Researchers and pharmaceutical companies have redirected their research and attention to the manufacturing of coronavirus vaccines and the treatment of Coronavirus, which hindered the market for CAR T-cells.

CAR T-Cell Therapy Market Segmentations: